518 related articles for article (PubMed ID: 18942092)
1. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
6. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
8. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
9. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
O'Donnell RT; DeNardo SJ; Miers LA; Lamborn KR; Kukis DL; DeNardo GL; Meyers FJ
Prostate; 2002 Jan; 50(1):27-37. PubMed ID: 11757033
[TBL] [Abstract][Full Text] [Related]
10. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
12. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
13. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
[TBL] [Abstract][Full Text] [Related]
15. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
17. Combined modality radioimmunotherapy. Promise and peril.
Burke PA; DeNardo SJ; Miers LA; Kukis DL; DeNardo GL
Cancer; 2002 Feb; 94(4 Suppl):1320-31. PubMed ID: 11877763
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Mortensen AC; Spiegelberg D; Haylock AK; Lundqvist H; Nestor M
Int J Oncol; 2018 Jun; 52(6):1875-1885. PubMed ID: 29658563
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.
Parry R; Schneider D; Hudson D; Parkes D; Xuan JA; Newton A; Toy P; Lin R; Harkins R; Alicke B; Biroc S; Kretschmer PJ; Halks-Miller M; Klocker H; Zhu Y; Larsen B; Cobb RR; Bringmann P; Roth G; Lewis JS; Dinter H; Parry G
Cancer Res; 2005 Sep; 65(18):8397-405. PubMed ID: 16166318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
